Table 1 Clinical characteristics of the patients with breast cancer
Patient | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|---|---|---|---|---|---|
Age (years) | 34 | 60 | 51 | 59 | 45 |
BMI | 23.7 | 19.6 | 25.1 | 17.8 | 30.7 |
Age at first period (years) | 14 | 15 | 15 | 13 | 14 |
Age at first birth (years) | 18 | 17 | 17 | 18 | 18 |
ECOG score [21] | 1 | 3 | 2 | 2 | 3 |
Preoperative lump size (cm) | 4 × 3 | 5 × 3 | 6 × 4 | 4 × 2 | 10 × 8 |
TNM Stage | T1N0MX | T4N0M0 | T2N1M0 | T2N0M0 | T2N2MX |
ER | Negative | Positive (80 %) | Positive (90 %) | Positive (80 %) | Negative |
PR | Negative | Positive (80 %) | Positive (85 %) | Negative | Negative |
HER2 | Positive (score: 3+) | Negative | Negative | Negative | Positive (score: 3+) |
Fish oil dosage (gm/day) | 1.2 | 1.8 | 1.8 | 1.8 | 1.8 |
No. of days of fish oil supplementation | 130 | 130 | 188a | 136 | 132 |
No. of capsules per day | Four | Six | Six | Six | Six |
Chemotherapy regimen | Adriamycin (72mg/100ml/10min), 5-fluorouracil (725mg/100ml/10min), cyclophosphamide (725mg/500ml/10min) | Doxorubicin (60mg/100ml/10min), 5-fluorouracil (685mg/100ml/10min), cyclophosphamide (685mg/500ml/60min) | Doxorubicin (70mg/100ml/10min), 5-fluorouracil (700mg/100ml/10min), cyclophosphamide (700mg/500ml/60min) | Paclitaxel (220mg/500ml/180min) | Doxorubicin (90mg/100ml/10min), 5-fluorouracil (900mg/100ml/10min), cyclophosphamide (900mg/500ml/60min) |